

SUPPORTIVE CARE COMMITTEE

CHELSEA HOTEL, TORONTO, ON

ROOM: CARLYLE A

APRIL 25, 2025, 8:00 AM – 12:00 PM

CO-CHAIRS : MICHAEL MCKENZIE & MARGOT BURNELL

SENIOR INVESTIGATOR: HARRIET RICHARDSON

CME Credits:

Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University

Learning Objectives:

1. To discuss the results of recent clinical trials in controlling symptoms of patients with cancer and the potential for translating this new knowledge
2. To discuss the role of psychosocial and other interventions such as psilocybin to alleviate cancer symptoms, improve treatment-related outcomes, and improve overall patient experience
3. To identify opportunities to expand the use of palliative radiotherapy for the management of symptoms
4. To discuss clinical trials in the field of early palliative care and to consider opportunities for research to support caregivers of cancer patients.
5. To identify opportunities to integrate new measurement methodologies and/or *correlative science* in supportive care trials.

8:00	Welcome new members including Wei Liu (new practicum trainee)	M.McKenzie/M. Burnell
8:05	SCC update: current and future priorities NCTN and CCS program grant preparation (2027)	M.McKenzie/M. Burnell
8:20	Patient priorities in research	H. Horlock
8:35	Results from CCS Breakthrough Team Grant competition in Supportive care and advanced cancer; next steps	
	SOPRANOS: remote symptom monitoring for immune-related toxicities	S. Lambert/D. Howell
	CAN-PACT: Psilocybin Assisted Therapy for demoralization in advanced cancer	L. Carlson/H.Richardson/R.Shore (Zoom)
	Palliative Care Network and new RCT platform	J. Downar (Zoom)



9:30	TRIAL PROPOSALS	
	High-dose psilocybin-assisted therapy (PAT) for fear of cancer recurrence (FCR) in cancer survivors. A phase II, randomized, controlled, double-blind, mixed-methods trial proposal	N. Giberson
	Vedolizumab for the Prevention of IO-Related Colitis	C. Ma
	*Announcement: Upcoming Supportive Care Pan Canadian Toxicity Symposium	K. Esfahani
10:00	Break	
10:15	Active/Approved trials and Secondary Data Analyses (5-10 minutes each)	
	CO.21: CHALLENGE Trial (Exercise & Colon Cancer)*	*Plenary Session
	SC.26: Emotion and Symptom-focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia	G. Rodin / C. Zimmermann
	SC.28: The Seamless study: A randomized waitlist-controlled trial evaluation of a smartphone app-based mindfulness intervention for cancer survivors	L. Carlson/H.Richardson
	SC.29: A Phase III Trial Comparing Stereotactic Body Radiotherapy versus Conventional Palliative Radiotherapy in Patients with Painful Non-Spine Bone Metastases"	T. Nguyen/A.Sahgal
	SC.30 RATIONAL TRIAL	A.Duarte
	SC.31 TEMPO	M. Fuchs (Zoom)
11:00	Special Topics	
	<ul style="list-style-type: none"> • Geriatric Research Agenda update <ul style="list-style-type: none"> • CNAC updates • Palliative Care Research Agenda <ul style="list-style-type: none"> • PCPCRC activities 	T. Hsu B. Hannon/ J. Lapenskie / C. Zimmermann
11:50	Wrap-Up and Meeting Adjourned	M.McKenzie/M. Burnell

